CA2673299C — Pyridazinone compounds for the treatment of proliferative diseases

USPTO Abstract

The invention concerns a compound having the formula: (see above formula) or pharmaceutically acceptable salts, isomers or tautomers thereof; for use in targeting an effector in the KRAS pathway. The invention also concerns the use of the above compound for treating, or in the manufacture of a medicament for treating a proliferative disease, such as a cancer. The invention further concerns a pharmaceutical composition comprising this compound or pharmaceutically acceptable salts, isomers or tautomers thereof, and at least one pharmaceutical acceptable excipient. The class of compounds was identified through screening of a collection of small molecules libraries.